- Home
- TVTX vs ELVN Comparison
TVTX vs ELVN Comparison
Compare TVTX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- ELVN
- Stock Information
- Founded
- TVTX 2008
- ELVN 2016
- Country
- TVTX United States
- ELVN United States
- Employees
- TVTX N/A
- ELVN N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- TVTX Health Care
- ELVN Health Care
- Exchange
- TVTX Nasdaq
- ELVN Nasdaq
- Market Cap
- TVTX 1.3B
- ELVN 1.3B
- IPO Year
- TVTX N/A
- ELVN 2020
- Fundamental
- Price
- TVTX $17.72
- ELVN $24.41
- Analyst Decision
- TVTX Buy
- ELVN Strong Buy
- Analyst Count
- TVTX 13
- ELVN 4
- Target Price
- TVTX $23.46
- ELVN $36.75
- AVG Volume (30 Days)
- TVTX 1.4M
- ELVN 243.2K
- Earning Date
- TVTX 10-31-2024
- ELVN 11-13-2024
- Dividend Yield
- TVTX N/A
- ELVN N/A
- EPS Growth
- TVTX N/A
- ELVN N/A
- EPS
- TVTX N/A
- ELVN N/A
- Revenue
- TVTX $203,447,000.00
- ELVN N/A
- Revenue This Year
- TVTX $62.45
- ELVN N/A
- Revenue Next Year
- TVTX $59.30
- ELVN N/A
- P/E Ratio
- TVTX N/A
- ELVN N/A
- Revenue Growth
- TVTX 57.08
- ELVN N/A
- 52 Week Low
- TVTX $5.12
- ELVN $9.80
- 52 Week High
- TVTX $20.33
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- TVTX 51.53
- ELVN 30.68
- Support Level
- TVTX $16.89
- ELVN $27.02
- Resistance Level
- TVTX $19.51
- ELVN $29.79
- Average True Range (ATR)
- TVTX 1.23
- ELVN 1.37
- MACD
- TVTX -0.16
- ELVN -0.60
- Stochastic Oscillator
- TVTX 26.69
- ELVN 11.67
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.